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Abstract
Background: Streptococcus pneumoniae is an important cause of morbidity and mortality in Southeast Asia, but regional
data is limited. Updated burden estimates are critical as pneumococcal conjugate vaccine (PCV) is highly effective, but not
yet included in the Expanded Program on Immunization of Thailand or neighboring countries.
Methods: We implemented automated blood culture systems in two rural Thailand provinces as part of population-based
surveillance for bacteremia. Blood cultures were collected from hospitalized patients as clinically indicated.
Results: From May 2005– March 2010, 196 cases of pneumococcal bacteremia were confirmed in hospitalized patients. Of
these, 57% had clinical pneumonia, 20% required mechanical ventilation, and 23% (n = 46) died. Antibiotic use before blood
culture was confirmed in 25% of those with blood culture. Annual incidence of hospitalized pneumococcal bacteremia was
3.6 per 100,000 person-years; rates were higher among children aged ,5 years at 11.7 and adults $65 years at 14.2, and
highest among infants ,1 year at 33.8. The median monthly case count was higher during December–March compared to
the rest of the year 6.0 vs. 1.0 (p,0.001). The most common serotypes were 23F (16%) and 14 (14%); 61% (74% in patients
,5 years) were serotypes in the 10-valent PCV (PCV 10) and 82% (92% in ,5 years) in PCV 13. All isolates were sensitive to
penicillin, but non-susceptibility was high for co-trimoxazole (57%), erythromycin (30%), and clindamycin (20%).
Conclusions: We demonstrated a high pneumococcal bacteremia burden, yet underestimated incidence because we
captured only hospitalized cases, and because pre-culture antibiotics were frequently used. Our findings together with prior
research indicate that PCV would likely have high serotype coverage in Thailand. These findings will complement ongoing
cost effectiveness analyses and support vaccine policy evaluation in Thailand and the region.
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Introduction
In 2009, The Hib and Pneumococcal Global Burden of Disease
Study Team estimated that Streptococcus pneumoniae caused nearly
5.5 million meningitis, sepsis, and pneumonia cases and .185,000
deaths in Southeast Asia annually, but noted that regional
prevention decisions, ‘will need to be made on the basis of limited
regional data’ [1]. Similarly, The Asian Strategic Alliance for
Pneumococcal Disease Prevention concluded that ‘pneumococcal
disease is an important cause of morbidity and mortality in the
Asian region’ and highlighted the ‘urgent’ need for ‘more
substantial studies’ describing invasive pneumococcal disease
burden in the Asia region [2].
Although WHO recommends pneumococcal conjugate vaccine
(PCV) vaccination even in the absence of local data, policymakers
often require local data to weigh costs and benefits [3]. Besides a
paucity of local data, policymakers in Southeast Asian countries
are faced with weighing the potential benefits of PCV against those
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of several other effective vaccines, including those against
rotavirus, influenza, and human papillomavirus. Currently, PCV
is not included in the National Expanded Programs of Immuni-
zation of Thailand or neighboring countries, though PCV it is
available on the private market in Thailand [4].
Cost reductions are anticipated as the PCV Advanced Market
Commitment is expected to increase demand, mass production,
and manufacturer competition [5]. We aim to provide local and
regional data to inform decision making as these changes occur.
Previously, we published the first population-based estimates of
pneumococcal bacteremia incidence in Southeast Asia [6]. The
purpose of this report is to update these estimates and to




The Thailand International Emerging Infections Program
(IEIP) is part of a collaboration between the Thailand Ministry
of Public Health and the U.S. Centers for Disease Control and
Prevention. We conduct surveillance for community-acquired
pneumonia requiring hospitalization in Sa Kaeo and Nakhon
Phanom provinces, where the combined populations total 1.2
million, including .80,000 children ,5 years [7]. Pneumonia
surveillance is conducted at all 18 district and military hospitals
and both provincial hospitals. Bloodstream infection surveillance
began in all hospitals in May 2005 in Sa Kaeo and in November
2005 in Nakhon Phanom with the implementation of automated
blood culture systems. Published detailed descriptions of these
surveillance systems are available, [6,8].
Patients
Physicians request blood cultures from hospitalized patients as
clinically indicated. Limited data (age, province, and pre-blood
culture antibiotic use) are available for patients who are in the
bloodstream infection surveillance system only. Detailed clinical
and demographic information is available for patients who were
also captured in the IEIP pneumonia surveillance system.
Specimen Collection and Laboratory Methods
Blood cultures collected at district hospitals were transported at
15–30uC within 24 hours and processed at provincial hospital
laboratories using the BactT/ALERTH 3D microbial detection
system (bioMeriéux). Each blood specimen was divided between a
bottle optimized for standard aerobic growth and a bottle for
enhanced growth of fastidious pathogens, with priority given to
inoculating at least 10 ml from adults and 4 ml from children ,5
years of age into the standard bottle. Bottles that signaled positive
growth (alarm-positive) were subcultured using standard methods
[9].
Serotyping was performed using multiplex polymerase chain
reaction (PCR) [10]. For isolates that could not be typed by this
method, Quellung serotyping was done at the Streptococcus
Reference Laboratory, U.S. Centers for Disease Control and
Prevention in Atlanta, Georgia. Antimicrobial susceptibilities were
determined by the disk-diffusion method with MIC values of
penicillin and cefotaxime determined by Etest (AB Biodisk).
Penicillin susceptibility interpretations used the 2008 Clinical and
Laboratory Standards Institute guidelines for non-meningitis
isolates: susceptible, #2 mg/ml; intermediate, 4 mg/ml; resistant
$8 mg/ml [11].
Antibiotic use before blood culture was determined by a serum
disc assay. A filter paper disc coated with patient serum was placed
onto a Mueller-Hinton agar plate inoculated with pan-sensitive
Staphylococcus aureus (ATCC 9144) and growth inhibition was
measured after 24 hours incubation at 35–37uC, [6,12].
Statistical Analysis
We calculated the observed (i.e., minimum) incidence of
pneumococcal bacteremia requiring hospitalization using person-
years of follow-up based on province specific annual population
estimates from the National Economic and Social Development
Board of Thailand [7]. Population estimates for infants were
obtained by applying the proportion of children ,1 year old
among all children ,5 years old nationally to the surveillance
population aged ,5 years [13]. Exact 95% confidence intervals
(CI) were calculated based on a Poisson distribution. Statistical
analyses were done using SAS version 9.2 (SAS Institute Inc.,
Cary, NC, USA).
Results
From May 2005 through March 2010, 5,118 of 67,516 (7.6%)
blood cultures performed in these 2 provinces were positive for any
pathogen, S. pneumoniae was isolated from the blood of 196 patients:
92 from Sa Kaeo province and 104 from Nakhon Phanom. S.
pneumoniae was isolated from 0.33% of 27,655 blood cultures in Sa
Kaeo compared to 0.26% (104/39,855) in Nakhon Phanom.
Among all patients with blood cultures, 25% were less than 5
years old and 25% were 65 years and older (Table 1). Deaths were
more common among patients with pneumococcal bacteremia
from Sa Kaeo: 37% (n = 34) in SK vs. 12% (n = 12) in NP.
Additional clinical details were available for 130 of 196 patients
with pneumococcal bacteremia who were also captured by IEIP’s
pneumonia surveillance system. Of these, 86% had respiratory
symptoms, 100% had evidence of acute infection and 86% (111/
130) had both, and thus met IEIP’s criteria for clinical pneumonia.
Pneumonia (ICD-10 codes J14–J19) was the discharge diagnosis
for 45% (58/130) and septicemia (ICD-10 code A41.9) for another
22% (29/130). Case-patients from Sa Kaeo were more likely to
receive oxygen or be intubated: oxygen use (77% in SK vs. 50% in
NP, p = 0.001), intubation (46% in SK vs. 16% in NP, p,0.001),
which is consistent with the higher case fatality rate observed in Sa
Kaeo.
Antibiotic use before blood culture was common; 25.4%
(11,123/43,720) of those tested had serum antimicrobial activity.
Among pneumococcal bacteremia cases, serum antimicrobial
activity was found in only 5 of the 135 tested (3.7%).
Hospitalized pneumococcal bacteremia incidence rates were
highest among young children and older adults and varied by year
(Figure 1). Overall incidence ranged from 2.3 per 100,000 person-
years in 2006 to 4.1 in 2009 (data for 2005 and 2010 were
incomplete and not considered). Among children less than 5 years
old, the highest annual incidence rate was observed in 2007: 18.5
per 100,000. Among infants ,1 year old, the average annual
incidence was 33.8 per 100,000 (95% CI 21.4, 50.7).
The median number of pneumococcal bacteremia cases per
month was significantly higher during December through March
compared to the rest of the year: 6.0 cases per month during
December-March vs. 1.0 during April-November (p,0.001)
(Figure 2). This difference was observed in both Sa Kaeo and
Nakhon Phanom provinces (data not shown).
Serotyping was completed for 191 (97%) of 196 isolates and 39
(98%) of 40 isolates from children ,5 years old. Serotypes 14 and
23F were most common among both children and adults; by
contrast, serotype 3 was common among adults, but not found in
children ,5 years.
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Among children aged ,5 years, serotypes contained in the
current 10- and 13-valent pneumococcal conjugate vaccines
(PCV10 and PCV13) comprised 74%, and 92% of cases,
respectively, exceeding the proportions among cases overall
(Figure 3).
Antibiotic susceptibility testing was available for 193/196
isolates with the results as follows: co-trimoxazole non-susceptibil-
Table 1. Clinical characteristics of patients with blood culture and hospitalized pneumococcal bacteremia cases in rural Thailand,
May 2005–March 2010.
All patients with blood
culture N = 67,516
All pneumococcal
bacteremia cases N = 196
Pneumococcal bacteremia
cases captured in pneumonia
surveillance N = 130
N % N % N %
Age
,5 16,908 25.0 40 20.4 26 19.9
5–19 6,532 9.7 20 10.2 12 9.2
20–49 14,700 21.8 50 25.5 31 23.7
50–64 12,341 18.3 36 18.4 26 19.9
65+ 17,029 25.2 50 25.5 36 27.5
Any respiratory symptoms
Cough – – – – 94 71.8
Dyspnea – – – – 70 53.4
Tachynea – – – – 29 22.8
Evidence of acute infection
Documented Fever – – – – 77 58.8
Fever History – – – – 115 87.8
Elevated White Blood Cell Count – – – – 72 55.0
Evidence of complicated illness
Oxygen – – – – 83 63.4
Intubation – – – – 40 30.5
Outcome
Discharge – – 110 56.1 81 61.8
Transfer – – 26 13.3 12 9.2
Death – – 46 23.5 31 23.7
Self-discharge – – 9 4.6 7 5.3
Missing – – 5 2.5 0 0.0
doi:10.1371/journal.pone.0066038.t001
Figure 1. Hospitalized pneumococcal bacteremia incidence rates by year and age in rural Thailand, May 2005 to March 2010. Overall
incidence 3.5 per 100,000 person-years, 95% CI (3.1, 4.1).
doi:10.1371/journal.pone.0066038.g001
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ity was 57% (n = 109); erythromycin 30% (n = 57); clindamycin
21% (n = 40); chloramphenicol 12% (n = 23). All isolates were
susceptible to penicillin and cefotaxime. Non-susceptibility to 3 or
more of the above antibiotics was observed in 18% (35/193).
Isolates with serotypes included in PCV10 were more likely to be
non-susceptible to co-trimoxazole, erythromycin, and clindamycin
compared to non-PCV10 serotype isolates: 63% vs. 45% for co-
trimoxazole; 42% vs. 10% for erythromycin; and 30% vs. 5.5% for
clindamycin.
Discussion
Based on 196 S. pneumoniae isolates collected during 4.4 years of
bloodstream infection surveillance in 2 rural provinces, we
estimated the overall incidence of hospitalization for pneumococ-
cal bacteremia in rural Thailand at 3.5 per 100,000 person-years.
Rates were highest among children ,5 years old (11.1 per 100,000
person-years) and adults 65 years and older (13.6 per 100,000
person-years).
These findings demonstrate that S. pneumoniae is an important
cause of severe disease requiring hospitalization in Thailand.
However, these data certainly underestimate the true incidence of
pneumococcal bacteremia. First, we only captured hospitalized
cases, and data from the United States suggest that most
pneumococcal bacteremia cases in young children occur among
outpatients [14]. Second, despite increased use of blood cultures
since implementation of automated blood culture processing in
2005, many patients who would likely have blood culture
performed in higher resource settings do not receive them in
rural Thailand. From May 2005 through June 2007, only 66% of
patients with indications for blood culture had a culture performed
and for patients ,5 years old the proportion was just 47% [6].
Furthermore, pre-culture antibiotic use remains common in this
setting. We recently examined this issue and estimated that pre-
culture antibiotics reduced our pneumococcal bacteremia inci-
Figure 2. Hospitalized pneumococcal bacteremia in 2 rural Thai provinces, May 2005-Mar 2010: a. Median monthly case counts, b.
Median monthly case counts during four consecutive December-March vs. April-November periods*. *p-values represent Wilcoxon
Rank Sum Test comparisons.
doi:10.1371/journal.pone.0066038.g002
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dence rates by 32% overall and 39% in children ,5 years of age
[12]. Finally, our surveillance does not include other manifesta-
tions of invasive pneumococcal disease, such as meningitis,
arthritis or osteomyelitis.
These incidence estimates are comparable to our previously
reported estimates examining 72 S. pneumoniae isolates from 23,853
blood cultures performed from May 2005 through June 2007 [6].
However, our previous report included estimates based on a
combination of cases identified via S. pneumoniae isolation and cases
identified only by Binax NOWH immunochromatographic test
(ICT) on broth of blood cultures that had a positive signal in the
BactT/ALERTH machine but were negative on sub-culture
(alarm positive, sub-culture negative). The current report does
not include these ICT-only cases, because more recent investiga-
tions indicate false-positive tests can occur [15] and we are
formally evaluating this unlicensed application of ICT. Alarm
positive, sub-culture negative bottles continue to pose a dilemma
in our laboratories; from January through March 2010, 89 (2.2%)
of 3891 blood cultures were alarm positive, sub-culture negative.
The proportion of fatal cases in Nakhon Phanom province
(12%) was comparable to that reported in other publications from
Thailand: 8.2% from Siripongpreeda et. al. (all invasive pneumo-
coccal disease), 16% from Netsawang et. al (non-meningitis),
13.3% (non-meningitis) in Suwanpakdee et al.[16–18]. By com-
parison, the case fatality rate in Sa Kaeo province (37%) seemed
unusually high. Unfortunately, data detailing clinical characteris-
tics, treatment, and underlying conditions were not available to
investigate this unusually high case fatality rate. However, our data
do suggest that severity of illness differed between the 2 provinces,
with substantially more patients in Sa Kaeo requiring oxygen and
intubation.
We documented consistent, statistically significant seasonal
increases in pneumococcal bacteremia from December through
March, which substantiates the seasonal increase noted in other
reports from Thailand [16], [17], [19], [20]. This seasonal pattern
coincides, approximately, with Thailand’s cool season (November
through February) and the seasonal increases in pneumococcal
disease observed in the U.S. and other temperate regions during
the winter months [21,22]. Interestingly, the pneumococcal
bacteremia peaks in Thailand occurred during opposite times of
year as Thailand’s usual influenza season [23,24], which differs
from temperate climates where invasive pneumococcal disease and
influenza peaks coincide [25]. This report includes data during the
2009 influenza pandemic, which first peaked in Thailand from
July to September 2009, during which time pneumococcal
bacteremia rates were low (Figure 2).
We observed that a high proportion of pneumococcal bacter-
emia cases among children aged ,5 years were caused by
serotypes covered by PCV10, and that with the addition of PCV13
serotypes, coverage increases from 74% to 92% for children ,5
years old and from 61% to 82% overall. In a 2010 report, Thai
researchers in the Bangkok area found that a similarly high
proportion of IPD cases among children aged ,5 years were
caused by vaccine serotypes: 70% and 81% for PCV7 and 13
respectively [26]. The Thailand National Institute of Health
reported even higher proportions of vaccine serotypes among
children aged ,5 years with invasive disease (80% for PCV10 and
92% for PCV13) [27]. Taken together these findings provide
strong evidence that high coverage could be expected from
PCV13 in Thailand.
All pneumococcal isolates were sensitive to penicillin, although
we observed high rates of antibiotic non-susceptibility to a variety
of other drugs, which is in agreement with many reports from
Thailand [16,18,19,28] and the region [29]. Our finding that
antibiotic non-susceptibility is significantly higher among PCV
serotypes corroborates other reports from Thailand and suggests
that enactment of PCV implementation could help reduce
Figure 3. Serotype distribution of isolates from pneumococcal bacteremia cases: limited to serotypes contained in PCV10 and
PCV13*. * Non-vaccine serotypes included: 11A (5 cases); 35B (3 cases); 7C, 10A, 23A, 34, (2 cases each), 8, 13, 15A, 15B, 16F, 18F, 20, 22F, 23B, 24F,
31, 35C, 35F and 38 (1 case each). The serotypes for five cases were not identified by the multiplex PCR protocol and these isolates were not available
for serotyping by other methods.
doi:10.1371/journal.pone.0066038.g003
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antibiotic non-susceptibility, as was seen in the U.S. after vaccine
introduction [30,31].
These findings document the ongoing burden of hospitalized
pneumococcal bacteremia, which represents a small fraction of the
total pneumococcal disease burden. In previous work among
adults, we found that blood culture alone underestimates the
incidence of hospitalized pneumococcal pneumonia cases by at
least 9-fold [32]. Taken together with recent reports from other
pneumococcal researchers in Thailand, our findings highlight the
potential impact of PCV in Thailand and underscore the need for
cost effectiveness data to inform vaccine policy discussions and
decision making.
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